Brief: EBR Systems Says FDA Commenced Substantive Review Of Its PMA Application
30/09/2024 02:24
Sept 30 (Reuters) - EBR Systems Inc EBR.AX :
* FDA COMMENCES SUBSTANTIVE REVIEW OF EBR'S PMA APPLICATION
* ANTICIPATES FDA'S REGULATORY APPROVAL IN Q1 CY2025
Source text for Eikon: ID:nASX9TRCQ7
Further company coverage: EBR.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on EBR Systems
See all newsAustralia's EBR Systems jumps on filing application for heart treatment
Brief: EBR Systems Submits TGA ARTG Application For Wise® System
Australia's EBR Systems hits record low on weak third-quarter revenue outlook
Brief: EBR Systems Forecasts Q3 2026 Revenue Of US$2.4 MLN To US$2.5 MLN
Brief: EBR Systems Announces Its Plan To Submit A Changes For Supplements To FDA In Q4 2026